Literature DB >> 25583712

Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.

Qiang Xia1, Li-Li Zhao2, Feng Li3, Yu-Mei Fan1, Yuan-Yuan Chen1, Bei-Bei Wu4, Zheng-Wei Liu4, Ai-Zhen Pan4, Min Zhu5.   

Abstract

To explore the phenotypic and genotypic characterization of pyrazinamide (PZA) resistance among multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates in Zhejiang province, a total of 274 MDR-TB isolates were collected. Drug susceptibility testing and spoligotyping were performed on all clinical isolates. In addition, the mutated features of PZA-resistant loci, including pncA and rpsA, were also analyzed by DNA sequencing. Our results showed that the prevalence of PZA resistance among MDR-TB strains in Zhejiang province was 43.07% and that PZA resistance was associated with concomitant resistance to streptomycin. The majority of PZA-resistant MDR-TB isolates belonged to the Beijing family. Mutations within pncA, not rpsA, constituted the primary mechanism of PZA resistance. Among 118 PZA-resistant isolates, 53 different mutations were observed in pncA, and most of them were point mutations. Compared with the phenotypic data, DNA sequencing of pncA has sensitivity and specificity of 77.97% and 96.79%, respectively. Analysis of pncA provided a robust tool for rapid detection of PZA drug resistance.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25583712      PMCID: PMC4325781          DOI: 10.1128/AAC.04541-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

Review 2.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

3.  Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis.

Authors:  Karolien Stoffels; Vanessa Mathys; Maryse Fauville-Dufaux; René Wintjens; Pablo Bifani
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

4.  Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA.

Authors:  David C Alexander; Jennifer H Ma; Jennifer L Guthrie; Joanne Blair; Pam Chedore; Frances B Jamieson
Journal:  J Clin Microbiol       Date:  2012-08-15       Impact factor: 5.948

5.  Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.

Authors:  H J Kim; H K Kwak; J Lee; Y J Yun; J S Lee; M S Lee; S Y Min; S K Park; H S Kang; Y H Maeng; S Y Kim; S Y Kim; Y H Kook; Y R Kim; K H Lee
Journal:  Int J Tuberc Lung Dis       Date:  2012-01       Impact factor: 2.373

6.  Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Sami O Simons; Jakko van Ingen; Tridia van der Laan; Arnout Mulder; P N Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2011-11-16       Impact factor: 5.948

7.  National survey of drug-resistant tuberculosis in China.

Authors:  Yanlin Zhao; Shaofa Xu; Lixia Wang; Daniel P Chin; Shengfen Wang; Guanglu Jiang; Hui Xia; Yang Zhou; Qiang Li; Xichao Ou; Yu Pang; Yuanyuan Song; Bing Zhao; Hongtao Zhang; Guangxue He; Jing Guo; Yu Wang
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

8.  Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.

Authors:  Jirarut Jonmalung; Therdsak Prammananan; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  BMC Microbiol       Date:  2010-08-20       Impact factor: 3.605

9.  Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting.

Authors:  Silke Feuerriegel; Barbara Oberhauser; Abu Garawani George; Foday Dafae; Elvira Richter; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  BMC Microbiol       Date:  2012-05-30       Impact factor: 3.605

10.  Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide.

Authors:  Stéphanie Petrella; Nathalie Gelus-Ziental; Arnaud Maudry; Caroline Laurans; Rachid Boudjelloul; Wladimir Sougakoff
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

View more
  31 in total

Review 1.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

2.  Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing.

Authors:  Kingsley King-Gee Tam; Kenneth Siu-Sing Leung; Gilman Kit-Hang Siu; Kwok-Chiu Chang; Samson Sai-Yin Wong; Pak-Leung Ho; Eunice Ka-Chun Leung; Wing-Cheong Yam
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

3.  Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.

Authors:  Peng Xu; Jie Wu; Chongguang Yang; Tao Luo; Xin Shen; Yangyi Zhang; Chijioke A Nsofor; Guofeng Zhu; Brigitte Gicquel; Qian Gao
Journal:  Tuberculosis (Edinb)       Date:  2016-03-03       Impact factor: 3.131

4.  Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010.

Authors:  Yu Pang; Zhijian Zhang; Yufeng Wang; Shengfen Wang; Yuanyuan Song; Bing Zhao; Yang Zhou; Xichao Ou; Qiang Li; Hui Xia; Yang Zheng; Xiangqun Fang; Yanlin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 5.  Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update.

Authors:  Ananthi Rajendran; Kannan Palaniyandi
Journal:  Curr Microbiol       Date:  2022-10-08       Impact factor: 2.343

6.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

7.  Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.

Authors:  Dange Li; Yi Hu; Jim Werngren; Mikael Mansjö; Xubin Zheng; Francis Drobniewski; Sven Hoffner; Biao Xu
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

8.  Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD.

Authors:  Pooja Gopal; Wilson Nartey; Priya Ragunathan; Jansy Sarathy; Firat Kaya; Michelle Yee; Claudia Setzer; Malathy Sony Subramanian Manimekalai; Véronique Dartois; Gerhard Grüber; Thomas Dick
Journal:  ACS Infect Dis       Date:  2017-10-18       Impact factor: 5.084

9.  Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.

Authors:  Yang Che; Dingyi Bo; Xiang Lin; Tong Chen; Tianfeng He; Yi Lin
Journal:  BMC Infect Dis       Date:  2021-06-25       Impact factor: 3.090

10.  The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?

Authors:  Steven T Pullan; Jon C Allnutt; Rebecca Devine; Kim A Hatch; Rose E Jeeves; Charlotte L Hendon-Dunn; Philip D Marsh; Joanna Bacon
Journal:  BMC Infect Dis       Date:  2016-05-17       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.